CTIS2022-502646-27-00招募中1 期
A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003) - MK-2140-003
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Has a histologically confirmed diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL)., Has radiographically measurable DLBCL per the Lugano response criteria, as assessed locally by the investigator., Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days prior to study treatment initiation., Has adequate organ function., Is able to provide new or archival tumor tissue sample not previously irradiated., Zilovertamab vedotin plus R-GemOx, or R-GemOx study arms: - Has relapsed or refractory DLBCL and is ineligible for or have failed autologous stem-cell transplant (ASCT) and have failed at least 1 line of prior therapy. - Has post-chimeric antigen receptor T (post-CAR-T) cell therapy failure or is ineligible for CAR-T cell therapy., Not Applicable: Zilovertamab vedotin plus Bendamustine Rituximab (BR), and Bendamustine Rituximab study arms: - Has relapsed or refractory DLBCL and is ineligible for or have failed ASCT and have failed at least 2 lines of prior therapy. - Has post-CAR-T therapy failure or is ineligible for CAR-T cell therapy.
排除标准
- •Not Applicable: Has history of transformation of indolent disease to DLBCL., Has contraindication to any of the study intervention components due to prior anaphylactic reaction., Has received prior systemic anticancer therapy, including investigational agents within 4 weeks prior to the first dose of study intervention., Has received prior radiotherapy within 4 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis., Has ongoing corticosteroid therapy., Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention., Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention., Has known active central nervous system (CNS) lymphoma involvement or active CNS involvement by lymphoma. Participants with prior CNS involvement are eligible if their CNS disease is in radiographic, cytological (for cerebrospinal fluid disease), and clinical remission., Has an active infection requiring systemic therapy., Has a known history of human immunodeficiency virus (HIV) infection., Has a known active Hepatitis C virus infection., Has received solid organ transplant at any time., Has a known psychiatric or substance abuse disorder that would interfere with the participant’s ability to cooperate with the requirements of the study., Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL)., Has clinically significant (ie, active) cardiovascular disease or serious cardiac arrhythmia requiring medication., Has ongoing graft-versus-host disease (GVHD) of any grade, or is receiving treatment for their GVHD., Has pericardial effusion or clinically significant pleural effusion., Has ongoing Grade >1 peripheral neuropathy., Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years., Has a demyelinating form of Charcot-Marie-Tooth disease.
研究者
相似试验
进行中（未招募）
1 期
A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate the most effective dose and the safety of medication MK-2140 when combined with standard treatments in patients with Diffuse Large B-Cell Lymphoma who failed prior therapies.Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell LymphomaMedDRA version: 21.1Level: LLTClassification code 10012857Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractorySystem Organ Class: 100000004864EUCTR2021-003313-18-PLMerck Sharp & Dohme LLC420
进行中（未招募）
1 期
A Randomized, Open-label, Multi-center, Phase 3, 2-arm Study Evaluating the Efficacy and Safety of Peg interferon Alfa-2b Low-dose Maintenance Monotherapy Versus Standard Supportive Care in Patients With Cirrhotic Hepatitis C Co-infected With Human Immunodeficiency Virus – The ENDURE Study. - ENDUREEUCTR2005-003876-39-BEIntegrated Therapeutics Group, Incorporated-a subsidiary of Schering Plough448
Unknown
2 期
umiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) (LUCID)CTRI/2009/091/000110Biogen Idec LtdBiogen Idec Limited
招募中
2 期
A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatmentrefractory Mycobacterium Avium Complex-lung Disease (MAC-LD)JPRN-jRCT2031200268akama Takahiro124
进行中（未招募）
1 期
A Clinical Trial to Compare the effectiveness and safety of Gan & Lee Pharmaceuticals Insulin Glargine Injection to Lantus® (Insulin Glargine Injection) in Adults with Type 2 Diabetes MellitusType 2 diabetes mellitusMedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-001415-36-HUGan & Lee Pharmaceuticals, USA554